Palomino Laboratories (PALX) Equity Average (2023 - 2025)
Palomino Laboratories recorded quarterly Equity Average of $7.7 million in Q4 2025, up 124.44% quarter-over-quarter from $3.4 million in Q3 2025, and up 57931.19% year-over-year from N/an in Q4 2024.
Palomino Laboratories' Equity Average history runs 3 years deep, the most recent figure standing at $7.7 million for Q4 2025.
- In Q4 2025, Equity Average rose 57931.19% year-over-year to $7.7 million; the TTM figure through Dec 2025 stood at $7.7 million (up 57931.19% YoY), while the FY2025 annual figure was $4.0 million, up 22167.58% from the prior year.
- Equity Average came in at $7.7 million for Q4 2025 at Palomino Laboratories, up from $3.4 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $7.7 million in Q4 2025 to a low of -$719444.5 in Q2 2025.
- A 3-year average of $809538.0 and a median of -$21501.8 in 2023 frame the typical range for Equity Average.
- On a YoY basis, Equity Average climbed as much as 66430.29% in 2025 and fell as far as 32871.79% in 2025.
- Palomino Laboratories' Equity Average stood at -$48486.5 in 2023, then soared by 72.52% to -$13324.5 in 2024, then surged by 57931.19% to $7.7 million in 2025.
- According to Business Quant data, Equity Average over the past three periods registered $7.7 million, $3.4 million, and -$719444.5 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.71 Mn |
| Sep 30, 2025 | 3.43 Mn |
| Jun 30, 2025 | -719,444.50 |
| Mar 31, 2025 | -504,979.50 |
| Dec 31, 2024 | -13,324.50 |
| Sep 30, 2024 | -5,176.00 |
| Jun 30, 2024 | -2,182.00 |
| Mar 31, 2024 | -2,231.50 |
| Dec 31, 2023 | -40,387.50 |
| Sep 30, 2023 | -57,235.50 |
| Jun 30, 2023 | -33,679.00 |
| Mar 31, 2023 | -29,679.00 |